Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Oncolys BioPharma Inc.. A complete text table follows the diagram.
R&D accounts for JPY1.017 billion of operating costs against JPY28.5 million of interim revenue and a JPY1.267 billion operating loss.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Research and development | 1 | 1.0B | 78.5% of reported total |
| Business consignment | 1 | 40.5M | 3.1% of reported total |
| Other selling, general and administrative | 1 | 238M | 18.4% of reported total |
| Operating costs | 2 | 1.3B | Six-month operating costs supporting the oncology pipeline |
| Operating loss | 2 | 1.3B | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 2.6B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Research and development | Operating costs | 1.0B |
| Business consignment | Operating costs | 40.5M |
| Other selling, general and administrative | Operating costs | 238M |
| Operating costs | Operating costs & expenses | 1.3B |
| Operating loss | Operating costs & expenses | 1.3B |